BRPI0414948A - derivados de pirazolo-e-imidazo pirimidina - Google Patents

derivados de pirazolo-e-imidazo pirimidina

Info

Publication number
BRPI0414948A
BRPI0414948A BRPI0414948-3A BRPI0414948A BRPI0414948A BR PI0414948 A BRPI0414948 A BR PI0414948A BR PI0414948 A BRPI0414948 A BR PI0414948A BR PI0414948 A BRPI0414948 A BR PI0414948A
Authority
BR
Brazil
Prior art keywords
pyrazolo
pyrimidine derivatives
derivatives
imidazo pyrimidine
imidazo
Prior art date
Application number
BRPI0414948-3A
Other languages
English (en)
Inventor
Juergen Wichmann
Thomas Johannes Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0414948A publication Critical patent/BRPI0414948A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

"DERIVADOS DE PIRAZOLO-E-IMIDAZO PIRIMIDINA". A presente invenção refere-se a novos derivados de pirazol- e imidazo-pirimidina de fórmula (I), em que A, D, E, L, M, Q, R¬ 1¬, R¬ 2¬ e R¬ 3¬ são como definido na descrição e reivindicações anteriores e a processos para sua preparação, composições farmacêuticas contendo os ditos derivados e seu uso na prevenção e tratamento de doenças.
BRPI0414948-3A 2003-10-03 2004-09-27 derivados de pirazolo-e-imidazo pirimidina BRPI0414948A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078075 2003-10-03
PCT/EP2004/010807 WO2005040171A1 (en) 2003-10-03 2004-09-27 Pyrazolo and imidazo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
BRPI0414948A true BRPI0414948A (pt) 2006-11-07

Family

ID=34486287

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414948-3A BRPI0414948A (pt) 2003-10-03 2004-09-27 derivados de pirazolo-e-imidazo pirimidina

Country Status (21)

Country Link
US (2) US7329662B2 (pt)
EP (1) EP1670801B1 (pt)
JP (1) JP4551402B2 (pt)
KR (2) KR20070096033A (pt)
CN (2) CN100522964C (pt)
AR (1) AR045959A1 (pt)
AT (1) ATE512148T1 (pt)
AU (1) AU2004283801B2 (pt)
BR (1) BRPI0414948A (pt)
CA (1) CA2540768C (pt)
CO (1) CO5680437A2 (pt)
ES (1) ES2364753T3 (pt)
HK (1) HK1099302A1 (pt)
IL (1) IL174512A0 (pt)
MX (1) MXPA06003526A (pt)
NO (1) NO20061363L (pt)
NZ (1) NZ546037A (pt)
RU (1) RU2350616C2 (pt)
TW (1) TWI297691B (pt)
WO (1) WO2005040171A1 (pt)
ZA (1) ZA200602677B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
NZ551660A (en) * 2004-06-21 2009-08-28 Hoffmann La Roche Pyrrazolo-pyrimidine derivatives and their use in diseases or conditions where mGluR2 activation plays a role
EP1851225B1 (en) * 2005-02-11 2011-06-15 F. Hoffmann-La Roche AG Pyrazolo-pyrimidine derivatives as mglur2 antagonists
CA2602444C (en) 2005-03-23 2013-03-19 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists
WO2007039439A1 (en) 2005-09-27 2007-04-12 F.Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
CA2693915A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
CN104662002A (zh) * 2012-07-27 2015-05-27 比亚尔-珀特拉和Ca股份公司 取代脲类化合物的合成方法
AU2013336863A1 (en) 2012-10-23 2015-03-19 F. Hoffmann-La Roche Ag MGlu2/3 antagonists for the treatment of autistic disorders
EP2958564B1 (en) 2013-02-21 2018-05-09 Calitor Sciences, LLC Heteroaromatic compounds as pi3 kinase modulators
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
CN104193745B (zh) * 2014-07-30 2016-09-28 斯芬克司药物研发（天津）股份有限公司 一种咪唑并嘧啶羧酸类化合物及其制备方法
AU2015295300B2 (en) * 2014-08-01 2019-05-02 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
ES2727158T3 (es) 2014-12-03 2019-10-14 Janssen Pharmaceutica Nv Ligandos para PET de mGluR2 radiomarcados
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
TWI733713B (zh) 2015-11-19 2021-07-21 美商纜圖藥品公司 用於治療神經促進性酪氨酸受體激酶相關之異常的化合物與組成物
WO2017103179A1 (en) 2015-12-18 2017-06-22 Janssen Pharmaceutica Nv Radiolabelled mglur2/3 pet ligands
AU2016374571B2 (en) 2015-12-18 2021-05-06 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 PET ligands
MX2020007521A (es) * 2018-01-17 2022-12-05 Glaxosmithkline Ip Dev Ltd Inhibidores de pi4kiii.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0880523T3 (da) 1996-02-07 2007-03-26 Neurocrine Biosciences Inc Pyrazolopyrimidiner som CRF-receptorantagonister
SK286461B6 (sk) * 1996-07-24 2008-10-07 Bristol-Myers Squibb Pharma Company [1,5-a]-Pyrazolo-1,3,5-triazíny, ich použitie a farmaceutické kompozície na ich báze
SI0891978T1 (en) * 1997-07-18 2002-06-30 F. Hoffmann-La Roche Ag 5H-Thiazolo (3,2-a) pyrimidine derivatives
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU79003A (sh) 2001-04-12 2006-05-25 F. Hoffmann-La Roche Ag. Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao mglur2 antagonisti ii
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine

Also Published As

Publication number Publication date
RU2006114749A (ru) 2007-11-20
EP1670801B1 (en) 2011-06-08
AR045959A1 (es) 2005-11-16
ZA200602677B (en) 2007-09-26
CN101239981A (zh) 2008-08-13
WO2005040171A1 (en) 2005-05-06
MXPA06003526A (es) 2006-06-08
JP4551402B2 (ja) 2010-09-29
CA2540768A1 (en) 2005-05-06
EP1670801A1 (en) 2006-06-21
AU2004283801B2 (en) 2010-04-22
KR100781469B1 (ko) 2007-12-03
TWI297691B (en) 2008-06-11
CA2540768C (en) 2011-08-09
US20050130992A1 (en) 2005-06-16
IL174512A0 (en) 2006-08-01
ES2364753T3 (es) 2011-09-13
NO20061363L (no) 2006-04-24
US7514443B2 (en) 2009-04-07
KR20060089731A (ko) 2006-08-09
NZ546037A (en) 2008-09-26
RU2350616C2 (ru) 2009-03-27
US7329662B2 (en) 2008-02-12
WO2005040171A8 (en) 2006-08-03
KR20070096033A (ko) 2007-10-01
TW200528453A (en) 2005-09-01
CN1890242A (zh) 2007-01-03
ATE512148T1 (de) 2011-06-15
CO5680437A2 (es) 2006-09-29
AU2004283801A1 (en) 2005-05-06
JP2007507446A (ja) 2007-03-29
CN100522964C (zh) 2009-08-05
US20080051421A1 (en) 2008-02-28
CN101239981B (zh) 2011-01-19
HK1099302A1 (en) 2007-08-10

Similar Documents

Publication Publication Date Title
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BR0108678A (pt) Novos compostos
BRPI0408347A (pt) derivados de pirimidina
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0312560A (pt) Novas espiropiperidinas ou espiropirrolidinas tricìclicas
BR0314379A (pt) Quinazolinonas espirocondensadas e a sua utilização como inibidores de fosfodiesterase
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0315665A (pt) Antagonistas de cgrp selecionados, processos para preparação dos mesmos, bem como uso dos mesmos como medicamento
BRPI0512677A2 (pt) derivados de quinazolina
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
SE0001899D0 (sv) New compounds
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
BR0208338A (pt) Derivados de piridina
BR0111319A (pt) Composto, processo para preparar um composto, uso de um composto, processo para preparar um sal de um composto, e, composto intermediário
BRPI0511933B8 (pt) derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica
BRPI0407734A (pt) derivados de adamantano, processo para sua preparação e composições farmacêuticas os contendo
BR0214666A (pt) Derivados de acetileno tendo atividade antagonìstica de mglur5
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
BR0314314A (pt) Derivados do éter 4-pirrolidina-fenil-benzìlico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 487/04; A61P 25/00

Ipc: C07D 487/04 (2011.01), A61P 25/00 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.